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The purpose of this study was to evaluate the standard outpatient dose of 131-Iodine tositumomab (75 cGy)
combined with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous
stem cell rescue for the treatment of chemotherapy-sensitive relapsed or refractory, or high-risk ﬁrst
complete remission (CR) patients with diffuse large B cell non-Hodgkin’s lymphoma (DLBCL). Forty patients
with chemotherapy-sensitive persistent or relapsed or high/intermediate or high international prognostic
index DLCBL were treated in a phase II trial combining 75 cGy 131-Iodine tositumomab with high-dose BEAM
followed by autologous stem cell transplantation. The CR rate after transplantation was 78%, and the overall
response rate was 80%. Short-term and long-term toxicities were similar to historical control patients treated
with BEAM alone. With a median follow-up of 6 years (range, 3-10 years), the 5-year overall survival (OS) was
72% (95% conﬁdence interval [CI], 55%-83%), and the 5-year progression-free survival (PFS) rate was 70% (95%
CI, 53%-82%). The PFS and OS were encouraging in this group of chemotherapy-sensitive persistent, relapsed,
or high-risk patients with DLBCL. A follow-up phase III trial with 131-Iodine tositumomab/BEAM vs ritux-
imab/BEAM was planned based on this information.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION before the collection of autologous stem cells, or in
Standard anthracycline-containing chemotherapy regi-
mens combined with rituximab produce a complete remis-
sion (CR) in approximately 60% to 80% of patientswith diffuse
large B cell lymphoma (DLBCL), which is associated with
long-term disease-free survival in approximately 40% to 80%
of patients depending on the patient characteristics [1-4].
Patients with persistent or recurrent DLBCL after a standard
anthracycline-based regimen, rarely have long-term disease-
free survival with standard salvage chemotherapy [5]. This is
particularly true in the rituximab era [6]. High-dose chemo-
therapy with autologous stem cell transplantation (ASCT) for
patients with persistent or recurrent DLBCL can achieve long-
term disease-free survival in approximately 30% to 60% of
patients [7-9]. Lymphomas also demonstrate radiosensitivity
in many cases, and localized radiation can be a useful adjunct
to the therapy [10]. In addition, total body irradiation (TBI)
has also been used as a part of conditioning regimens for stem
cell transplantations [11,12]. However, results with standard
high-dose chemotherapy and ASCT have not been optimized,
and concerns about the use of TBI for short- and long-term
side effects have led to alternative methods for trans-
plantation preparative regimens being developed.
Monoclonal Abs such as rituximab have recently been
added to the transplantation preparative regimen, useddgments on page 127.
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[13,14]. Additionally, several pilot trials using radio-
immunotherapy either alone or in combination with high-
dose chemotherapy followed by ASCT have been published
[15-17]. In an initial phase I study, high-dose radio-
immunotherapy with 131-Iodine tositumomab followed by
ASCT was administered to patients with relapsed B cell non-
Hodgkin lymphoma (NHL) [15]. In subsequent studies, high-
dose 131-Iodine tositumomab was given with dose-intense
etoposide and cyclophosphamide followed by ASCT in an
attempt to substitute the 131-Iodine tositumomab for TBI in
the transplantation regimen [17]. The maximum dose in the
combination trial that could be administered with etoposide
60 mg/kg and cyclophosphamide 100 mg/kg was a 131-
Iodine tositumomab dose of 25 Gy to critical normal
organs. The preliminary results from this study were
encouraging with the estimated overall survival (OS) and
progression-free survival (PFS) of all treated patients at 2
years to be 83% and 68%, respectively.
Because the high doses of 131-Iodine tositumomab used
with this approach require specialized facilities for the
administration and radiation isolation for the patients, it was
difﬁcult to perform at some centers. Subsequently, a phase I
trial combining standard outpatient dosing of 131-Iodine
tositumomab with high-dose chemotherapy for the treat-
ment of resistant NHL was performed [18]. In this trial,
patients with chemoresistant NHL demonstrated an unex-
pectedly high overall response rate of 65% with a median
follow-up of 38 months, a PFS of 39%, and an OS rate of 55%
[18]. Based upon the promising results in the phase I trial,
this phase II trial in patients whowere DLBCL transplantationTransplantation.
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Figure 1. Schema for 131-Iodine carmustine, etoposide, cytarabine, and
melphalan (BEAM) transplantation program.
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disease was undertaken.
PATIENTS AND METHODS
Eligibility
Patients who were age 19 to 75 years of age with persistent or relapsed
DLBCL or who had high intermediate or high-risk disease by International
Prognostic Index [19] were eligible. The patients needed to have a Karnofsky
Performance Status of 70 to be eligible. Patients had chemotherapy-
sensitive disease, deﬁned as at least a 50% reduction of persistent or relapsed
DLBCL according to the criteria in effect at the time of the protocol. Patients
were required to have adequate cardiac and pulmonary function, deﬁned as
a left ventricular ejection fraction of45% and a corrected carbon monoxide
diffusing capacity of 50%. Additional eligibility criteria included a calcu-
lated creatinine clearance of 50 mL/min. Patients needed <20% bone
marrow (BM) involvement with lymphoma. Patients needed to have BM
with no evidence of myelodysplastic syndrome before entry into the
protocol. In addition, the patients needed to be able to collect >1.5  106
CD34þ cell/kg peripheral blood progenitor cells for the transplantation. The
protocol was approved by the scientiﬁc advisory board, radiation safety, and
institutional review boards of the University of Nebraska Medical Center. All
patients signed appropriate informed consent forms in effect for the study in
accordance with the Declaration of Helsinki.
Treatment Protocol: Antibody Dosimetric Dose
After >1.5  106 CD34þ cells/kg peripheral blood progenitor cells were
obtained after ﬁlgrastimmobilization, the patients received their dosimetric
dose of 131-Iodine tositumomab (Figure 1). This was given on day19 of the
transplantation protocol. Orally administered saturated solution of potas-
sium iodide with 2 drops 3 times daily was given for thyroid blockade
starting 1 day before the dosimetric dose and was continued for 14 days
after the therapeutic dose of 131-Iodine tositumomab. The murine mono-
clonal anti-CD20 (tositumomab; GlaxoSmithKline, Philadelphia, PA) was
radio iodinated with sodium 131-Iodine (speciﬁc activity, 296 GBq/mg; New
England Nuclear, Boston, MA) by the Iodogenmethod, puriﬁed, and tested as
described previously [20]. Patients were premedicated with acetaminophen
650 mg and diphenhydromine 50 mg orally before the administration. Then
patients received 450 mg unlabeled tositumomab i.v. followed by a trace
labeled 5 mCi (35 mg) 131-Iodineelabeled tositumomab dose. Vital signs
were recorded every 15 minutes during the Ab administration. All dosi-
metric and therapeutic administrations were performed in the outpatient
cancer treatment area.
Within 1 hour after the dosimetric dose of 131-Iodine tositumomab and
before urination, a whole body quantitative gamma camera image was ob-
tained for baseline readings. Additional scans were performed on days 2, 3,
or 4, and day 6 or 7 after the dosimetric dose. Using this information, the
radioactive clearance from each patient was obtained to determine the
radioactive millicurie activity of 131-Iodine tositumomab required to deliver
the desired therapeutic dose 1 week later. Themethodology for determining
the patient-speciﬁc millicurie activity was performed in accordance
with the Medical Internal Radiation Dose Primer for Absorbed Dose Calcu-
lations [21].
Therapeutic Infusions
One week later, on day 12 of the transplantation protocol, the thera-
peutic dose of 131-Iodine tositumomab was administered on an outpatient
basis. The patients were again premedicated with acetaminophen 650 mg
and diphenhydramine 50 mg orally. Subsequently, 450 mg of unlabeled
tositumomab was administered i.v. over 1 hour. This was followed by the
patient-speciﬁc dose calculated for administration based on the whole bodygamma camera images. Patients were treated with 75 cGy total body dose
131-Iodine tositumomab. The millicurie dose for the therapeutic dose was
calculated based on the actual body weight for patients weighing 137% of
their lean body weight and at 137% of the lean body weight for those
patients weighing more than 137% of their lean body weight. Vital signs
were taken every 15 minutes during the infusion of the Ab.
Outpatient release criteria were used from the Nuclear Regulatory
Commission guidelines [22]. These criteria authorize patient release
according to a dose-based limit, which is the dose to individuals exposed to
the patient (<0.5 rem). The dose-based limit addresses the public safety
issue of radioactivity, which is governed by the Nuclear Regulatory
Commission.
High-Dose Chemotherapy Administration
Starting on day 6 of the transplantation protocol, patients received
carmustine 300 mg/M2 i.v. On days 5 to 2, they received etoposide 100
mg/M2 twice daily (8 doses total) and cytarabine 100 mg/M2 twice daily (8
doses total) i.v., and on day1, they receivedmelphalan 140 mg/M2 once i.v.
The following day (day 0), the patients received their previously collected
unpurged autologous peripheral blood progenitor cells. The patients
received hematopoietic growth factors with ﬁlgrastim (neupogen, gran-
ulocyte colony-stimulating factor) 5 ug/kg subcutaneously starting on
day þ7 after the transplantation and continuing until the absolute neutro-
phil count was 500/mm3 for 3 consecutive days. Patients received 2 units
of irradiated packed RBCs if their hemoglobin was 8 gm/dL and a single-
donor irradiated platelet count if their platelet count was <10,000/uL. In
addition, they received standard broad-spectrum antibiotic therapy for
associated neutropenic fever and antifungal antibiotics for persistent fevers
according to a standard transplantation protocol.
Evaluation of Toxicity
Toxic effects were assessed by using the National Cancer Institute
Common Toxicity Criteria, version 3 [23].
Follow-Up
Patients were staged for their extent of lymphoma before the stem cell
transplantation, at day þ100 after the transplantation, at yearly intervals
posttransplantation, and as clinically appropriate. Patients underwent
computed tomography scans of the chest, abdomen, and pelvis, physical
examinations, complete blood count, and chemistry proﬁles at these time
points. In addition, if the patients had a positive BM at any point, it was
repeated, and optional tests also included a positron emission tomography
scan. In addition, the patients had a baseline thyroid-stimulating hormone
tested, and it was repeated at dayþ100 and yearly thereafter. If the patients
had evidence of unexplained cytopenias, a BM biopsy for cytogenetics and
analysis was obtained.
Statistical Analysis
The primary objective included the examination of potential efﬁcacy
with evaluation of the complete and overall remission rates (ORRs), PFS, and
OS. For these purposes, the CR rate was deﬁned as the complete disap-
pearance of all lymph nodes previously >1.5 cm and BM negativity when
previously positive. A partial response (PR) was deﬁned as 50% reduction
in the bidimensional sum of the products of all lymph nodes. Responses
were evaluated according to the 1999 International Workshop Response
Criteria [24]. Both PFS and OS were calculated using the Kaplan-Meier
method [25]. PFS was deﬁned as all patients whowere alive at last follow-up
with no documented relapse or progression of their disease. OS was deﬁned
as all patients who were alive at their last follow-up whether their disease
had progressed or not.
A priori power calculations showed that using PFS as the endpoint,
assuming an improvement from 40% to 80% PFS, a sample of 40 patients has
power of 93% using a 2-sided alpha of 0.05.
RESULTS
Patient Information
Forty patients were entered in the study between March
2000 and September 2005. The characteristics of the patients
are summarized in Table 1. The patients ranged in age from
26 to 75 years of age (median, 54 years). All patients had
DLBCL, which was conﬁrmed by central pathology review
(W.C.C. and D.D.W.). Thirty-ﬁve patients (88%) had received
prior rituximab, and 9 (22%) had received prior involved ﬁeld
irradiation. Eleven patients (28%) had received 1 prior
chemotherapy regimen, 23 (58%) had received 2 prior
Table 2
Grade III and IV Nonhematologic Toxicities
Toxicity Grade III-IV Events (%) of Patients
Gastrointestinal: anorexia 2 (5)
Diarrhea 2 (5)
Esophagitis 2 (5)
Hyperbilirubinemia 1 (3)
Ileus 2 (5)
Nausea/vomiting 2 (5)
Stomatitis 6 (16)
Cardiac: atrial ﬁbrillation 4 (10)
Congestive heart failure 1 (3)
Syncope 1 (3)
Pulmonary: pneumonia 4 (10)
Pleural effusion 1 (3)
Infections: bacteremia/sepsis 8 (20)
Clostridium difﬁcile colitis 3 (8)
Varicella zoster 3 (8)
Renal: renal insufﬁciency 1 (3)
Secondary malignancy - AML 2 (5)
AML indicates acute myelogenous leukemia.
Table 1
Patient Characteristics
Variable No. of Patients (%)
No. of patients 40
Median age in years (range) 54 (26-75)
Male sex 25 (62)
White race 38 (95)
Prior use of rituxan 35 (88)
Prior use of radiation 9 (22)
No. of prior chemotherapy treatments
One 11 (28)
Two 23 (58)
Three or more 6 (14)
Type of prior chemotherapy
CHOP 9 (22)
R-CHOP 27 (68)
Others 4 (10)
Ann Arbor staging before transplantation
Stage I-II 11 (28)
Stage III-IV 14 (35)
CR 13 (33)
Unknown 2 (4)
LDH > normal at transplantation 13 (32)
BM involvement at transplantation 1 (2)
Extranodal involvement at transplantation 11 (28)
Disease stage at transplantation
First CR 13 (33)
Primary induction failure - chemosensitive 5 (12)
Relapse - chemosensitive 22 (55)
Median time from diagnosis to transplantation in
months (range)
15 (5-200)
Less than 1 year 15 (38)
Greater than or equal to 1 year 25 (62)
Year of transplantation
2000-2001 9 (22)
2002-2003 14 (35)
2004-2005 17 (43)
Median time to follow-up among survivors in
years (range)
6.89 (3.09-11.04)
CHOP indicates cyclophosphamide, doxorubicin, vincristine, prednisone; R-
CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone;
CR, complete response; LDH, lactic dehydrogenase; BM, bone marrow.
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status at transplantation included patients in primary
induction failure (chemosensitive) (N ¼ 5), high-risk CR1
(N ¼ 13), and chemosensitive relapsed disease (N ¼ 22).Toxicity
The grade III and IV toxicities are listed in Table 2. All
patients had the expected grade III/IV hematologic toxicities
severe myelosuppression (neutrophils <0.5  109/L and
platelets <20  109/L) during transplantation. However, all
patients engrafted with the median time to neutrophil
engraftment (the ﬁrst of 3 consecutive days of 0.5  109/L)
10 days (range, 8-30 days), the median time to platelet
independence (the ﬁrst of 7 consecutive days with a platelet
count 20,000/uL) was 12 days (range, 10-100þ days), and
the median time to RBC transfusion independence (the ﬁrst
of 30 consecutive days of a hemoglobin 8 gm/dL) was 9
days (range, 8-100þ days). These were similar to 120
historical control patients receiving carmustine, etoposide,
cytarabine, and melphalan (BEAM) alone in which the
median time to neutrophil engraftment was 11 days (range,
9-35 days), the median time to platelet independence was 12
days (range, 9-100þ days), and the median time to RBC
transfusion independence was 10 days (range, 8-100þ days).
Nonhematologic toxicity was similar to controls as well, as 7
patients had a bacteremia, and 1 patient had a sepsis
syndrome. Five patients had pneumonia, 4 patients had atrialﬁbrillation, and 1 patient had renal insufﬁciency. Three
patients had grade I to II, and 6 patients had grade III to IV
stomatitis. There were no deaths within the ﬁrst 100 days
after the transplantations.Response to Therapy
The response rate was assessed at day þ100 after the
transplantation. The patients were restaged with physical
examination, computed tomography scans, and BM biopsy
(when indicated). The CR rate was 31 of 40 (78%), and the
ORR was 32 of 40 (80%).OS and PFS
With a median follow-up of 6 years (range, 3-10 years),
the 5-year PFS was 70% (95% conﬁdence interval [CI]
53%-82%) (Figure 2A), and the 5-year OS was 72% (95% CI,
55%-83%) (Figure 2B). When evaluating the outcomes by
pretransplantation response, the 5-year PFS for patients in
CR1 was 85% (95% CI, 51-96), ﬁrst PR (chemosensitive) was
100%, and for relapsed chemosensitive was 54% (95% CI,
32-72) (Figure 3). The 5-year OS for the patients in CR1 was
85% (95% CI, 52-96), ﬁrst PR was 100%, and relapsed DLBCL
was 63% (95% CI, 40-80). For the 10 patients who relapsed
12 months from diagnosis, the 5-year PFS was 38%
compared to 58% for those who relapsed >12 months from
diagnosis (P ¼ .86). For the patients who relapsed 12
months from diagnosis, the 5-year OS was 58% compared to
80% for those who relapsed>12months (P¼ .25). The causes
of death included progressive lymphoma in 9 patients (69%),
secondary malignancy (acute myelogenous leukemia [AML])
in 2 patients (15%), bacterial infection in 1 patient (8%), and
thromboembolism in 1 patient (8%).Long-Term Complications
Two patients developed myelodysplastic syndrome/AML
at 13 and 58 months posttransplantation, respectively. They
both died from AML. Both patients had cytogenetics abnor-
malities at the time of myelodysplastic syndrome develop-
ment consistent with alkylating agent exposure, cumulative
chemotherapy, and/or radiotherapy with monosomy 5 and
monosomy 7, respectively. One additional patient developed
prostate cancer, 1 patient developed anal cancer, and 1
patient developed squamous cell carcinoma of the skin. Nine
Figure 2. (A) Progression-free survival for patients treated with 131-Iodine tositumomab/carmustine, etoposide, cytarabine, and melphalan (BEAM) and autologous
stem cell transplantation (ASCT). (B) Overall survival for patients treated with 131-Iodine tositumomab/BEAM and ASCT.
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thyroid hormone replacement.
DISCUSSION
Although initial rituximab containing anthracycline
chemotherapy can produce high response rates and long-
term disease-free survival in a majority of patients with
DLBCL, between 20% and 50% of patients either fail to go into
remission or relapse after an initial response [3,4]. In addi-
tion, standard salvage chemotherapy is not felt to be curative
for patients with DLBCL [5,6]. High-dose chemotherapy and
ASCT has produced approximately 40% to 50% long-term
survivors in patients with chemotherapy-sensitive relapsed
disease [7,9]. If patients are in primary induction failure, but
still have disease that is somewhat chemotherapy sensitive,
the results with transplantation may be higher at a 30%
PFS [8]. The addition of rituximab to the transplantation
program has produced excellent long-term outcomes [13,14].
However, as all of the patients with DLBCL are now receiving
rituximab as part of their initial therapy, patients who
relapse do not seem to beneﬁt from additional rituximab in
the posttransplantation setting [26]. Therefore, optimization
of transplantation methods is an important area of research
to improve these outcomes.
Radiolabeled monoclonal Abs have recently emerged as
an effective new treatment for patients with relapsed B cell
lymphomas [18,27]. Studies using radioimmunotherapy at
nonmyeloablative doses have produced response rates of
60% to 80% for 131-Iodine and 90-Yttriumelabeled anti-
CD20 Abs [18,27-29]. The median duration of responses
varied from 6 to 18 months in these trials; however, some
CRs have been maintained for up to 6 to 8 years [29,30].Figure 3. (A) Progression-free survival for patients who underwent transplantation in
cell lymphoma (DLBCL) (N ¼ 22). (B) Overall survival for patients who underwent
relapsed DLBCL (N ¼ 22).Because myelosuppression is the major toxicity associ-
ated with radioimmunotherapy, it is an ideal candidate
to combine with high-dose chemotherapy and ASCT.
The majority of the early studies combining radio-
immunotherapy with transplantation have included high-
dose myeloablative 131-Iodine tositumomab either alone
[15,16] or in combination with high-dose etoposide and
cyclophosphamide [17]. The single agent myeloablative
regimen tested in patients with a variety of relapsed
lymphomas produced OS and PFS rates of 68% and 42%,
respectively [15,16]. The combination regimen of etoposide,
cyclophosphamide with myeloablative 131-Iodine tositu-
momab, and ASCT produced OS and PFS rates of 83% and
68% in patients with chemotherapy-sensitive relapsed NHL
[17]. However, a concern with these high-dose 131-Iodine
myeloablative regimens is the radiation safety issues and
specialized facilities necessary for the administration of
these agents.
High-dose 90-Yttrium ibritumomab in doses up to 15 Gy
to critical organs combined with BEAM has also recently
been used as part of a conditioning regimen for ASCT [31]. In
this study byWinter et al. [31], 44 patients were treated with
this combination. With a median follow-up of 33 months for
all patients, the estimated 3-year PFS and OS were 43% and
60%, respectively. In another study, high-dose 90-Yttrium
ibritumomab tiuxetan was combined with high-dose eto-
poside 40-60 mg/kg and cyclophosphamide 100 mg/kg [32].
The 90-Yttrium ibritumomab tiuxetan was delivered to
a target dose of 1,000 cGy highest dose to a normal organ. In
this study, with a median follow-up of 22 months, the 2-year
OS and relapse-free survival rates were 92% and 78%,
respectively [32].ﬁrst partial response (N ¼ 5), high-risk CR1 (N ¼ 13), or relapsed diffuse large B
transplantation in ﬁrst partial response (N ¼ 5), high-risk CR1 (N ¼ 13), and
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momab tiuxetan have also been combined with the BEAM
protocol (Z-BEAM) in 2 recent studies. In a study from the
Groupe d’Etude des Lymphomes de l’Adulte group, 77
patients with chemosensitive relapsed or refractory indolent
lymphoma received this protocol. The 2-year event-free
survival and OS were 63% and 97%, respectively, with
a good safety proﬁle [33]. A second recent study of Z-BEAM
evaluated 43 patients with relapsed CD20þ NHL. Twenty-
two patients were randomized to Z-BEAM and 21 patients
to BEAM alone [34]. In this small study, the 2-year OS was
91% in the Z-BEAM and 62% in the BEAM arm, respectively
(P ¼ .05) [34].
The trial outlined in this article was a phase II trial
combining standard dose 131-Iodine tositumomab (75 cGy)
with a standard BEAM transplantation protocol. A prior
phase I pilot trial was conducted in patients with refractory
lymphoma and had promising outcomes with a total CR rate
of 57% and an ORR of 65% [18]. In the phase I study, with
a follow-up of 38months, the OSwas 55%, and the event-free
survival was 39%. With those encouraging results, the larger
phase II study adding 75 cGy total body dose 131-Iodine
tositumomab to BEAM and autologous transplantation in
patients with chemotherapy-sensitive relapsed diffuse large
B cell lymphoma was conducted. This preparative regimen
was shown to be safe and with a promising 5-year PFS of 70%
and OS of 72% in this phase II trial.
However, it is difﬁcult to compare all of these trials
because of the small numbers of patients, different histolo-
gies of lymphoma in the trials, and different patient pop-
ulations. A subsequent large phase III randomized study to
compare 131-Iodine tositumomab/BEAM to rituximab/BEAM
with standard ASCT has been subsequently performed to
compare these techniques [35]. In 224 randomized patients
with relapsed chemosensitive DLBCL, the 2-year PFS was 49%
in the 131-Iodine tositumomab/BEAM arm compared to 49%
in the rituximab/BEAM arm (P ¼ .65). The 2-year OS was also
not different between the 2 arms (60% and 66%, respectively)
(P ¼ .29). Although a large phase III trial with the use of
90-Yttrim ibritumomab has not been conducted to date,
a matched-cohort analysis was done comparing Z-BEAM to
TBI-based regimens [36]. In this study, the 4-year OS was
better for the Z-BEAM protocol compared to the TBI-based
regimens (81% vs 53%; P ¼ .01). This seemed to mostly be
related to higher nonrelapse mortality in the TBI group
(0% compared to 15%, P < .01) [36].
The speciﬁc type of histology of NHL may be very
important for the use of radioimmunotherapy as part of the
transplantation regimen. The patients with indolent or
mantle cell lymphomas seem to have had an improved
beneﬁt from this addition. In addition, it may be that much
higher doses of radioimmunotherapy are necessary to ach-
ieve improvement in the outcome of these patients.
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